Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous vs intravenous ultra-low dose rituximab in rheumatoid arthritis
2020-002507-19Phase 4Completed
- Sponsor
- Sint Maartenskliniek
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rituximab in rheumatoid arthritis (RA) (2 arms), sponsored by Sint Maartenskliniek. Primary endpoint: Non-inferiority of SC vs IV rituximab based on AUC0-6 months. Started Sep 2020; status: completed.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2020-002507-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002507-19.